RWA Wealth Partners LLC Buys 1,058 Shares of Cencora, Inc. $COR

RWA Wealth Partners LLC raised its stake in shares of Cencora, Inc. (NYSE:COR) by 3.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,164 shares of the company’s stock after acquiring an additional 1,058 shares during the quarter. RWA Wealth Partners LLC’s holdings in Cencora were worth $10,544,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. AE Wealth Management LLC lifted its holdings in Cencora by 6.6% during the 2nd quarter. AE Wealth Management LLC now owns 20,792 shares of the company’s stock valued at $6,234,000 after purchasing an additional 1,283 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Cencora during the second quarter worth about $448,000. Vestmark Advisory Solutions Inc. acquired a new stake in shares of Cencora during the second quarter worth approximately $4,233,000. Atlas Legacy Advisors LLC boosted its stake in Cencora by 31.3% in the second quarter. Atlas Legacy Advisors LLC now owns 4,207 shares of the company’s stock worth $1,261,000 after purchasing an additional 1,004 shares in the last quarter. Finally, Savant Capital LLC raised its holdings in Cencora by 8.4% during the 2nd quarter. Savant Capital LLC now owns 8,251 shares of the company’s stock worth $2,474,000 after purchasing an additional 639 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several analyst reports. Wells Fargo & Company increased their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Mizuho boosted their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Finally, UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $351.50.

Cencora Price Performance

Shares of Cencora stock opened at $360.56 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $69.90 billion, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $364.36. The company has a 50-day simple moving average of $314.27 and a two-hundred day simple moving average of $299.34.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the company posted $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a $0.60 dividend. The ex-dividend date is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.